Hemispherian | BiotechTV

top of page

Swiss Nordic Bio 2026: Hemispherian's oncology approach is to target the TET2 enzyme - with the aim to restore the cancer cell’s normal epigenetic complement

CEO Zeno Albisser describes this target and the company's work to focus on it - their lead asset is in the clinic and is partnered with BioLineRx. Coverage brought to you by

Company News

2 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page

Swiss Nordic Bio 2026: Hemispherian's oncology approach is to target the TET2 enzyme - with the aim to restore the cancer cell’s normal epigenetic complement

Follow BiotechTV

Sponsors

Sponsor Spotlight